近年来,多特异性药物加速走向临床与商业化:PD-1/VEGF双抗以头对头关键临床数据对标现有标准疗法,双特异性ADC、靶向自免热门靶点TL1A的双抗、三特异性T细胞衔接器加速推进临床。但繁荣之下,挑战不容回避。大量双抗、多抗管线扎堆申报,同质化竞争愈演愈烈,而真正经过临床验证的技术路径仍然有限——能做出来的分子越来越多,能走到终点的路径依然有限。那么,分水岭在哪?
多特异性药物的分野,不在“双抗”还是“三抗”的命名里,而在命名之后的每一环:从分子构型设计、工艺开发与规模化生产的CMC壁垒,到跨境技术合作与授权交易,每一步取舍,都在影响产品能否走向成功。
卡点不破,项目走不到终点。这一期,只谈卡点。11月17日20:00,本周二由凯莱英生物联合E药经理人携手推出的《大国新药·国际版》第三期节目,将以“从双抗到三抗:全球新药创新的下一波浪潮”为主题开播。六位重磅嘉宾将围绕多特异性药物的真实价值、差异化创新机会与跨境合作的可行路径,展开深度对话。
嘉宾简介向上滑动查看
主持人:
Leon ‘Jun’ Tang
PhD, MS, ISWT Community
Dr. Leon ‘Jun’ Tang is the founding partner of InScienceWeTrust BioAdvisory (ISWT BioAdvisory), a life sciences consulting firm focused on East-West cross-border BD&L and R&D collaboration, which has advised more than 30 biotech companies, investment funds, and other life sciences companies. Since February 2026, he has also served as Vice President of the Mianus Accelerator at Mianus Capital, focusing on early-stage biotech investment andfirst-in-human clinical development.
Dr. Tang founded iSWT Community, a U.S.-based nonprofit with more than 5,000 active members from the Asian biotech community, and hosts the BioVerse webinar series. Previously, he was Head of BD Search & Evaluation at Shanghai Henlius Biotech, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager at the philanthropic venture fund of the Cancer Research Institute.
He has published more than 50 papers in journals including Nature Reviews Drug Discovery, Lancet Oncology, and Science Translational Medicine. He received his bachelor’s degree from Tianjin University, his master’s degree from Nankai University, and his PhD from the Icahn School of Medicine at Mount Sinai, and completed postdoctoral training at Memorial Sloan Kettering Cancer Center.
分享嘉宾:
Jing Li
Founder and CEO, VelaVigo
Dr. Jing Li is the founder and CEO of VelaVigo. Under his leadership, the company has raised $160 million, out-licensed two preclinical programs in deals with total value of more than $1.2 billion, and advanced two first-in-class programs into global clinical trials.
Before founding VelaVigo, Dr. Li was Senior Vice President at WuXi Biologics. He previously served as Senior Manager of Portfolio & Alliance Management at the Novartis Biologics Center, Lab Head and Program Team Head at Novartis Oncology, and Senior Scientist and Project Leader at Wyeth (now Pfizer).
Dr. Li has more than 30 years of experience in antibody engineering and 25 years in industry drug discovery and development. He has filed more than 70 patent applications and authored more than 20 publications, and Harvard Business School has adopted VelaVigo’s founding journey as a case study. He received his MD and PhD in molecular immunology and oncology from Peking University Health Science Center, his MBA from the Yale School of Management, and completed postdoctoral training at Tufts University.
Stephen Yoder
CEO, Red Ridge Bio
Stephen Yoder is President and CEO of RedRidge Bio, a combinatorial biology company developing bispecific antibodies, including biparatopics that bind two epitopes on one target, in oncology and autoimmunity. RedRidge runs a fully integrated East-West R&D model, with strategy anchored in the U.S. and Basel, Switzerland, and execution in Shanghai.
The company has an oncology-focused R&D collaboration with Pierre Fabre and a proprietary pipeline in oncology and autoimmune disease, with its first IND forecast for 2027. RedRidge is Series A-funded in a round co-led by Versant and NEA.
Previously, Mr. Yoder was CEO of Pieris Pharmaceuticals for 15 years and General Counsel and head of business development at MorphoSys.
Liangsu Wang
Co-Founder and CSO,
Caldera Therapeutics
Dr. Liangsu Wang is a biopharmaceutical executive and entrepreneur with nearly 30 years of experience in drug discovery, development, and R&D strategy. As Co-Founder and CSO of Caldera Therapeutics, she leads scientific strategy and portfolio development.
Previously, she founded BioSage Advisors and held senior leadership positions at Johnson & Johnson, Morphic Therapeutic, and Merck. At Johnson & Johnson, she was Vice President and Therapeutic Area Head of External Innovation, leading strategic partnerships and investments across multiple disease areas. At Morphic, she helped establish the company’s scientific strategy and pipeline, initiated its lead IBD program, MORF-057, and contributed to its financing and IPO; Eli Lilly acquired Morphic for $3.2 billion in 2024. Before Morphic, she was Executive Director and Head of Diabetes and NASH Discovery Research at Merck.
Dr. Wang holds a PhD from the University of Calgary and a BS from Fudan University.
Zhen Su
President and CEO,
Marengo Therapeutics
Dr. Zhen Su has been CEO and a member of the Board of Marengo Therapeutics since July 2021. Marengo’s lead program, invikafusp alfa (STAR0602), is a first-in-class bispecific dual T-cell agonist that selectively activates Vβ T-cell subsets together with an IL-2 signal. He has also served on the Board of Directors of Karyopharm Therapeutics since 2023.
Previously, Dr. Su was Senior Vice President and Global Head of the Oncology Business Franchise at Merck KGaA, and concurrently US Head of its Oncology Business Unit, and earlier Chief Medical Officer of EMD Serono. He held leadership roles of increasing responsibility at Sanofi Oncology and GSK. Earlier in his career, he was a faculty member at Duke University Medical School, where he led early oncology studies of mRNA-based and cell-based immunotherapy, and Director of the Cell and Gene Therapy program at the University of Florida.
Dr. Su received his MD from the Technical University of Dresden, Germany, and his MBA from the University of Toronto.
Dandan Dong
Managing Partner, TCGX Capital
Dr. Dandan Dong is a Managing Partner at TCGX, which closed its oversubscribed $600 million Asia Life Sciences Fund I in October 2026. She joined TCGX to lead its venture formation effort and brings more than 15 years of global healthcare investment and biotech operating experience.
Before TCGX, Dr. Dong was Chief Business Officer of ArriVent Biopharma, where she played an essential role in company formation, acquired the ex-China rights to its core asset, furmonertinib, and was instrumental in the company’s private and public financings.
Earlier, she was Managing Director at Vivo Capital and General Partner of the Vivo PANDA Fund and Innovation Fund II. She incubated cross-border biotech companies including Visen Pharmaceuticals, a joint venture with Ascendis Pharma, where as founding CBO and executive board member she led pipeline acquisition, corporate strategy, recruitment, and financing. She also co-founded RareStone Group, the first rare disease ecosystem in Greater China.
作为本期节目的主办方,凯莱英生物长期深耕生物药的开发与生产。从分子早期研发、工艺开发到规模化放大,复杂抗体药物的每一步突破,都离不开扎实的平台能力支撑。依托覆盖早期研发(AccPCC一体化技术平台)、工艺开发到临床及商业化生产的 CDMO 服务体系,凯莱英生物持续赋能抗体药物创新,支持单抗、双抗等复杂分子项目的推进,并与行业同仁共同观察三抗等下一代抗体从设计走向临床的可能路径。
11月17日(周二)20:00,【大国新药】第三期将在微信视频号开播,我们一起把"从双抗到三抗"这条全球新药创新的下一波浪潮聊清楚。